In clinical trials1,3,4Evidence: Smaller human trialsMetabolic and weight

VK27353

Key takeaway

VK2735 is an experimental dual agonist of the GLP-1 and GIP receptors, studied for weight management.3 In the 13-week phase 2 VENTURE trial in adults with obesity or overweight, average weight loss was 9.1% to 14.7% depending on strength, compared with 1.7% on placebo; side effects were mainly gastrointestinal.3 No FDA approval is reported in the sources reviewed here, and it is not among the six peptides in HHS’s October 2026 draft enforcement-discretion policy.3,4,6

VK2735 at a glance

What it isAn investigational glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide (GLP-1/GIP) receptor dual agonist, according to the VENTURE trial report.3
FDA statusNot FDA-approved. No FDA approval is reported in the sources reviewed here, and phase 3 trials are registered on ClinicalTrials.gov.1,3
Human evidenceOne published 13-week phase 2 randomized, double-blind, placebo-controlled trial in adults with obesity or overweight.3
Evidence strengthSmaller controlled human trials. The cited sources include randomized or otherwise controlled human trials that are fully reported in a journal article or in posted registry results, but none meets the large-trial rule. How this label is assigned

What is VK2735?

VK2735 is an investigational drug that activates both the GLP-1 receptor and the GIP receptor, according to the 2026 VENTURE trial report.3

How is VK2735 thought to work?

As a GLP-1/GIP receptor dual agonist, it is designed to activate both receptors. The VENTURE trial tested whether this reduces body weight.3

What do human studies show?

VENTURE randomly assigned adults with obesity, or overweight and at least one weight-related condition, and without diabetes, to one of several strengths of VK2735 or placebo for 13 weeks, between August 2023 and February 2024.3

Average weight loss was 9.1% to 14.7% with VK2735 and 1.7% with placebo. In the VK2735 groups, 130 of 140 participants lost at least 5% of their weight, compared with 4 of 34 on placebo.3

The most common side effects were gastrointestinal and became less frequent with continued use, according to the report.3

What the evidence base contains

  • Controlled human trial VENTURE (NCT06068946): a 13-week phase 2 randomized, double-blind, placebo-controlled trial in adults with obesity or overweight and at least one weight-related condition, in which 93% of those on VK2735 lost at least 5% of their weight, compared with 12% on placebo.3

Evidence-strength label: Smaller controlled human trials. How this label is assigned

Is VK2735 FDA-approved?

None of the sources reviewed here reports an approval of VK2735 by FDA.3,4

ClinicalTrials.gov lists a phase 3 trial of VK2735 for weight loss as recruiting in its November 16, 2026 record, and another phase 3 trial as active, not recruiting in its April 7, 2026 record.1,2

FDA’s compounding safety-risk page, current as of April 22, 2026, does not list VK2735.4

HHS’s October 30, 2026 draft enforcement-discretion policy lists six peptides in its Appendix A: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. VK2735 is not among them.5,6

Timeline

  1. The 13-week phase 2 VENTURE trial of VK2735 is published.3

What is still unknown?

Its effects and safety beyond 13 weeks and in larger groups of people, which the published phase 2 trial did not address.3

PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.

Go deeper

Records, reviews and history

Everything PeptideScanner has collected for VK2735: reviews, official-source readings, registry and literature records, and every change to this profile.

What the trial and literature lists cover. The trials and papers listed for VK2735 are a bounded selection, not every registration or paper about VK2735. For the years before VK2735 was added, PeptideScanner took at most 25 ClinicalTrials.gov registrations that list VK2735 as an intervention: trials with posted results first, then later-phase trials, then the most recently updated. It also took at most 25 PubMed papers that name VK2735 in the title: randomized controlled trials, clinical trials, meta-analyses, systematic reviews and reviews first, then the most recent. Records that also named another tracked peptide, or that failed the publication checks, were left out. A daily check adds newly updated registrations and newly indexed papers that pass the same checks. How records are selected.

Status brief and reviewed-evidence summary

Evidence summary

What the cited records show

What is its status in the cited records?

In clinical trials; not FDA-approved. Published evidence is one 13-week phase 2 randomized trial. VK2735 is not on FDA’s compounding safety-risk page and is not among the six peptides in HHS’s October 2026 draft policy.↗↗↗↗

Status sources checked through November 14, 2026. See status sources and coverage →

Research records

Explore this profile’s cited source records →

An editorial human-evidence summary has not yet been published.

Explore status sources, recent additions, and coverage gaps

Living status brief

What is the current status of VK2735?

In clinical trials; not FDA-approved. Published evidence is one 13-week phase 2 randomized trial. VK2735 is not on FDA’s compounding safety-risk page and is not among the six peptides in HHS’s October 2026 draft policy.↗↗↗↗

The cited status sources were checked through November 14, 2026. This answer changes only through the profile’s visible version and correction history.

Evidence present

What records are connected here?

Evidence lanes
1
Source years
2
Drugs@FDA applications
0

These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.

Latest source-dated record

What changed most recently at a cited source?

Clinical trials · source date November 16, 2026

ClinicalTrials.gov record NCT07868835↗Added to PeptideScanner November 16, 2026

Coverage gaps

What remains unknown or unsupported?

PeptideScanner currently has no selected PubMed literature metadata records, regulatory records, and safety records connected to this profile. That is a collection gap, not evidence that no such records exist.

PeptideScanner does not infer an answer where the cited records do not provide one. Open the source-linked records below to inspect their scope and limits.

Explore the Evidence Map and record counts

Evidence Map v1

What kinds of records connect to VK2735?

Compare collection coverage →

This map describes PeptideScanner’s selected, source-linked collection. It is not an evidence grade and does not establish research quality, safety, effectiveness, or medical relevance.

6Selected dated records
10Connected citations
2Populated source years2025–2026
1/4Record lanes present

Registered human studies

Trial composition

6 of 6 selected trial records include at least one phase value; 6 of 6 include a status value in the retained structured contract.

PhasesPhase 3 3Phase 2 2Phase 1 1
Status at observationCompleted 3Active, not recruiting 2Recruiting 1

PubMed bibliography

Publication composition

0 of 0 selected PubMed records include attributed title, venue, publication date, and publication-type fields.

Regulatory and publication surfaces

What is structurally connected?

Drugs@FDA applications
0
FDA Federal Register documents
0
DailyMed SPL versions
0
Canonical profile
Published
Profile structured data
Published
Linked dated records
6

Application counts reflect exact reviewed ingredient connections; Federal Register counts reflect exact reviewed peptide-name matches; DailyMed counts reflect listed SPL versions with retained ZIP receipts. “Published” describes this page’s indexing surface, not the state of scientific evidence.

Profile publication history and record counts
Source records by collection · 6 dated records

Research hub

Explore the VK2735 evidence record

Open all 6 records →
6Dated records
1Evidence type
6Cited public sources
2Source years

Change ledger

Recently changed for VK2735

Open all 6 events →

PeptideScanner change dates and cited source dates stay separate. These entries report collection or version activity, not a ranking of importance.

Record added

ClinicalTrials.gov record NCT05203237

PeptideScanner retained ClinicalTrials.gov record NCT05203237 at 2026-11-16T17:46:36.579Z. Its registry update date was 2025-02-17, and PeptideScanner's reviewed identity mapping was vk2735.

PeptideScanner change date
November 16, 2026
Cited source date
February 17, 2025
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT06068946

PeptideScanner retained ClinicalTrials.gov record NCT06068946 at 2026-11-16T17:46:36.579Z. Its registry update date was 2025-02-12, and PeptideScanner's reviewed identity mapping was vk2735.

PeptideScanner change date
November 16, 2026
Cited source date
February 12, 2025
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT06828055

PeptideScanner retained ClinicalTrials.gov record NCT06828055 at 2026-11-16T17:46:36.579Z. Its registry update date was 2025-10-06, and PeptideScanner's reviewed identity mapping was vk2735.

PeptideScanner change date
November 16, 2026
Cited source date
October 6, 2025
Evidence lane
Clinical trials

Official-source collections

Source records for VK2735

Open the full research atlas →
ClinicalTrials.gov6

0 public history versions across these dated registry records; status labels apply only to each cited observation.

  1. NCT07868835Registry update November 16, 2026 · current at observation
  2. NCT07104383Registry update April 7, 2026 · current at observation
  3. NCT07104500Registry update November 24, 2025 · current at observation
Explore all selected trial records →Explore all public record history →

Evidence types

Coverage by source year

Selected records span February 12, 2025 to November 16, 2026. These dates come from selected source records and PubMed metadata, not a complete or continuous timeline of research, safety, approval, or effectiveness.

Continue exploring

Profiles with overlapping source-year coverage

Open the research atlas →

These links are based only on overlapping years and evidence lanes in PeptideScanner’s selected records. They do not imply that the peptides are medically or scientifically similar.

Organizations and trial records named in cited sources

Organizations named in cited records

  • U.S. Food and Drug Administration4
  • U.S. Department of Health and Human Services5
Dated updates connected to this profile · 6

Updates connected to this profile

Open the full cross-source timeline →
  1. Clinical trials

    ClinicalTrials.gov record NCT07868835↗

    PeptideScanner retained ClinicalTrials.gov record NCT07868835 at 2026-11-16T17:46:36.579Z. Its registry update date was 2026-11-16, and PeptideScanner's reviewed identity mapping was vk2735.↗

  2. Clinical trials

    ClinicalTrials.gov record NCT07104383↗

    PeptideScanner retained ClinicalTrials.gov record NCT07104383 at 2026-11-16T17:46:36.579Z. Its registry update date was 2026-04-07, and PeptideScanner's reviewed identity mapping was vk2735.↗

  3. Clinical trials

    ClinicalTrials.gov record NCT07104500↗

    PeptideScanner retained ClinicalTrials.gov record NCT07104500 at 2026-11-16T17:46:36.579Z. Its registry update date was 2025-11-24, and PeptideScanner's reviewed identity mapping was vk2735.↗

  4. Clinical trials

    ClinicalTrials.gov record NCT06828055↗

    PeptideScanner retained ClinicalTrials.gov record NCT06828055 at 2026-11-16T17:46:36.579Z. Its registry update date was 2025-10-06, and PeptideScanner's reviewed identity mapping was vk2735.↗

  5. Clinical trials

    ClinicalTrials.gov record NCT05203237↗

    PeptideScanner retained ClinicalTrials.gov record NCT05203237 at 2026-11-16T17:46:36.579Z. Its registry update date was 2025-02-17, and PeptideScanner's reviewed identity mapping was vk2735.↗

  6. Clinical trials

    ClinicalTrials.gov record NCT06068946↗

    PeptideScanner retained ClinicalTrials.gov record NCT06068946 at 2026-11-16T17:46:36.579Z. Its registry update date was 2025-02-12, and PeptideScanner's reviewed identity mapping was vk2735.↗

Citations

Sources

Coverage and sources →

Numbered markers in the text point here. Each link opens the original public record.

  1. 1
    ClinicalTrials.gov record NCT07868835 · retained source version 2026-11-16:754cc17245a18215ce0d3940312a9a7ada00032d9098c9032f6a189cf2f02123 ↗

    ClinicalTrials.gov · Official source · Source checked November 16, 2026

  2. 2
    ClinicalTrials.gov record NCT07104383 · retained source version 2026-04-07:2c8e771eae38a675ce6f376d5c356c4c03943ee4ecfe103d4bbbfc65c43428cd ↗

    ClinicalTrials.gov · Official source · Source checked November 16, 2026

  3. 3
    Weekly subcutaneous VK2735, a GIP/GLP-1 receptor dual agonist, for weight management: phase 2, randomized, 13-week VENTURE study (2026) · PMID 41508550 ↗

    Obesity · Official source · Source checked November 16, 2026

  4. 4
    Certain bulk drug substances for use in compounding that may present significant safety risks ↗

    U.S. Food and Drug Administration · Official source · Source checked November 14, 2026

  5. 5
    Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances · notice of availability · 91 FR 68526 · October 30, 2026 ↗

    Federal Register · U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026

  6. 6
    HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendix A (list of peptides) and Appendix B (identities and justifications) ↗

    U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026